Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1990 1
1995 1
1996 1
1998 1
2003 1
2008 1
2010 2
2012 1
2013 2
2015 2
2016 2
2017 4
2018 4
2019 8
2020 4
2021 8
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Nuñez NG, et al. Among authors: fruh m. Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381 Free article.
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Rothschild SI, et al. Among authors: fruh m. J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12. J Clin Oncol. 2021. PMID: 34251873 Free article. Clinical Trial.
METHODS: Neoadjuvant treatment consisted of three cycles of cisplatin 100 mg/m(2) and docetaxel 85 mg/m(2) once every 3 weeks followed by two doses of durvalumab 750 mg once every 2 weeks. ...
METHODS: Neoadjuvant treatment consisted of three cycles of cisplatin 100 mg/m(2) and docetaxel 85 mg/m(2) once every 3 weeks …
Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Boesch M, Baty F, Rothschild SI, Tamm M, Joerger M, Früh M, Brutsche MH. Boesch M, et al. Among authors: fruh m. Br J Cancer. 2021 Aug;125(3):313-323. doi: 10.1038/s41416-021-01365-2. Epub 2021 Apr 6. Br J Cancer. 2021. PMID: 33824481 Free PMC article. Review.
Fine particulate matter and polycystic ovarian morphology.
Fruh V, Cheng JJ, Aschengrau A, Mahalingaiah S, Lane KJ. Fruh V, et al. Environ Health. 2022 Feb 18;21(1):26. doi: 10.1186/s12940-022-00835-1. Environ Health. 2022. PMID: 35180862 Free PMC article.
RESULTS: Cumulative exposure to PM(2.5) during the study ranged from 4.9 to 17.5 g/m(3) (mean = 10.0 mug/m(3)). On average, women were 31 years old and 58% were Black/African American. ...No appreciable differences were observed across race/ethnicity. Among women wi …
RESULTS: Cumulative exposure to PM(2.5) during the study ranged from 4.9 to 17.5 g/m(3) (mean = 10.0 mug/m(3)). On average, wo …
Characterization of a live-attenuated HCMV-based vaccine platform.
Caposio P, van den Worm S, Crawford L, Perez W, Kreklywich C, Gilbride RM, Hughes CM, Ventura AB, Ratts R, Marshall EE, Malouli D, Axthelm MK, Streblow D, Nelson JA, Picker LJ, Hansen SG, Früh K. Caposio P, et al. Among authors: fruh k. Sci Rep. 2019 Dec 17;9(1):19236. doi: 10.1038/s41598-019-55508-w. Sci Rep. 2019. PMID: 31848362 Free PMC article.
[Treatable immune-mediated neuropathies].
Steck AJ, Früh J. Steck AJ, et al. Among authors: fruh j. Schweiz Med Wochenschr. 1995 Jun 17;125(24):1216-22. Schweiz Med Wochenschr. 1995. PMID: 7597412 Review. German.
Correlates of Persistent Endocrine-Disrupting Chemical Mixtures among Reproductive-Aged Black Women.
Schildroth S, Wise LA, Wesselink AK, De La Cruz P, Bethea TN, Weuve J, Fruh V, Botelho JC, Sjodin A, Calafat AM, Baird DD, Claus Henn B. Schildroth S, et al. Among authors: fruh v. Environ Sci Technol. 2021 Oct 19;55(20):14000-14014. doi: 10.1021/acs.est.1c02549. Epub 2021 Sep 30. Environ Sci Technol. 2021. PMID: 34591461 Free PMC article.
Older age (per 1 year increase: beta = 0.47, CI = 0.39, 0.54; OR = 1.27, CI = 1.20, 1.35), lower body mass index (per 1 kg/m(2) increase: beta = -0.14, CI = -0.17, -0.12; OR = 0.91, CI = 0.89, 0.94), and current smoking (10 cigarettes/day vs never smokers: beta = 1.37, CI …
Older age (per 1 year increase: beta = 0.47, CI = 0.39, 0.54; OR = 1.27, CI = 1.20, 1.35), lower body mass index (per 1 kg/m(2) incre …
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
Joerger M, Omlin A, Cerny T, Früh M. Joerger M, et al. Among authors: fruh m. Curr Drug Targets. 2010 Jan;11(1):37-47. doi: 10.2174/138945010790030974. Curr Drug Targets. 2010. PMID: 19839929 Review.
Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for patients with advanced non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin, and as single agent for relapsed or chemotherapy refractory NSCLC after platinum-contain …
Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for patients with advanced non-squamous, non-small cell …
Covid-19 vaccination and menstrual cycle length in the Apple Women's Health Study.
Gibson EA, Li H, Fruh V, Gabra M, Asokan G, Jukic AMZ, Baird DD, Curry CL, Fischer-Colbrie T, Onnela JP, Williams MA, Hauser R, Coull BA, Mahalingaiah S. Gibson EA, et al. Among authors: fruh v. NPJ Digit Med. 2022 Nov 2;5(1):165. doi: 10.1038/s41746-022-00711-9. NPJ Digit Med. 2022. PMID: 36323769 Free PMC article.
43 results